CJC-1295 without DAC dosage: reported doses and schedule
A peptide intended to trigger growth hormone release, with no human dosing study found.
Also called: Modified GRF 1-29, Mod GRF 1-29, Mod GRF(1-29), CJC-1295 no DAC.
GHRH analogues · Modified GHRH 1-29 analogue without an albumin-binding DAC tag.
Typical reported dose: 100–200 mcg at bedtime, often with ipamorelin
- Nightly no-DAC pairing: 100–200 mcg no DAC plus 100–200 mcg ipamorelin once nightly, under the skin. Reported by users, common report. Studied in: Adult self-users reporting online; identity, dose and outcomes are unverified. (source)
- Morning and bedtime report: 100 mcg no DAC in the morning; 200 mcg at bedtime twice daily, under the skin. Reported by users, occasional report. Studied in: Adult self-users reporting online; identity, dose and outcomes are unverified. (source)
- 300 mcg, five nights weekly: 300 mcg no DAC plus 300 mcg ipamorelin at bedtime nightly, five days on and two days off, under the skin. Reported by users, occasional report. Studied in: Adult self-users reporting online; identity, dose and outcomes are unverified. (source)
- Forum cycle described in a review: 100–200 mcg per injection, once or twice daily once or twice daily, under the skin. Reported by users, common report. Studied in: Adult self-users reporting online; identity, dose and outcomes are unverified. (source)
- Single high-dose outlier: 2 mg daily, reported by one commenter once daily, under the skin. Reported by users, rare report. Studied in: Adult self-users reporting online; identity, dose and outcomes are unverified. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to CJC-1295 without DAC
- Tesamorelin: A peptide approved for deep abdominal fat in adults with HIV lipodystrophy.
- Sermorelin: An experimental short-acting peptide that triggers growth hormone release, with limited evidence of adult benefits.
- CJC-1295 with DAC: An experimental long-acting peptide that triggers growth hormone release, with no proven muscle or recovery benefit.
- Ipamorelin: An experimental peptide that triggers growth hormone release.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Concerns regarding the public health risks associated with unapproved peptide products, Therapeutic Goods Administration and Chief Medical Officer · Therapeutic Goods Administration · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- EGRIFTA WR (tesamorelin) for injection, for subcutaneous use, U.S. Food and Drug Administration · FDA · 2025
- Supply unlicensed medicinal products (specials), MHRA · 2025
- December 4, 2024 Pharmacy Compounding Advisory Committee Meeting, FDA · 2024
- FDA Briefing Document Pharmacy Compounding Advisory Committee (PCAC) Meeting December 4, 2024, US Food and Drug Administration · 2024
- Low blood sugar (hypoglycaemia), NHS · 2023
- Anticoagulant medicines - Side effects, NHS
- DailyMed - GLUCOTROL XL- glipizide tablet, extended release, Pfizer Inc. · DailyMed
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.